Xilio Therapeutics, INC. (XLO) — 8-K Filings

8-K Filings (21)

• Xilio Therapeutics Files 8-K on Officer Changes — Apr 16, 2026 Risk: low
  On April 16, 2026, Xilio Therapeutics, Inc. filed an 8-K report detailing changes in its executive officers and compensatory arrangements. The filing specifical
• 8-K Filing — Nov 25, 2025
• Xilio Therapeutics Files 8-K — Nov 7, 2025 Risk: low
  Xilio Therapeutics, Inc. filed an 8-K on November 7, 2025, reporting on Item 8.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
• Xilio Therapeutics Faces Delisting Notice — Oct 3, 2025 Risk: high
  Xilio Therapeutics, Inc. filed an 8-K on October 3, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company's principa
• Xilio Therapeutics Files 8-K Report — Sep 9, 2025 Risk: low
  On September 9, 2025, Xilio Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indica
• Xilio Therapeutics Faces Delisting Concerns — Aug 28, 2025 Risk: high
  Xilio Therapeutics, Inc. filed an 8-K on August 28, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earlie
• Xilio Therapeutics Files 8-K on Shareholder Vote — Jun 12, 2025 Risk: low
  Xilio Therapeutics, Inc. filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of security holders on June 10, 2025. The filing details the co
• Xilio Therapeutics Board Changes: New Directors Elected, Two Depart — Jun 10, 2025 Risk: medium
  On June 10, 2025, Xilio Therapeutics, Inc. filed an 8-K report detailing the departure of two directors, Dr. Jeffrey W. Allen and Dr. Steven M. Altschuler, effe
• Xilio Therapeutics Files 8-K: Material Agreement, Other Events — Jun 3, 2025 Risk: medium
  On June 2, 2025, Xilio Therapeutics, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and reported other even
• Xilio Therapeutics Files 8-K — Jun 2, 2025 Risk: low
  Xilio Therapeutics, Inc. filed an 8-K on June 2, 2025, reporting events as of May 31, 2025. The filing primarily concerns financial statements and exhibits, alo
• Xilio Therapeutics to be Delisted from Nasdaq — Apr 8, 2025 Risk: high
  Xilio Therapeutics, Inc. announced on April 4, 2025, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The co
• Xilio Therapeutics Files 8-K on Financials — Mar 11, 2025 Risk: low
  On March 11, 2025, Xilio Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• Xilio Therapeutics Files 8-K: Material Agreement & Equity Sales — Feb 12, 2025 Risk: medium
  On February 10, 2025, Xilio Therapeutics, Inc. entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securitie
• Xilio Therapeutics Files 8-K — Jan 21, 2025 Risk: low
  Xilio Therapeutics, Inc. filed an 8-K on January 21, 2025, reporting on other events and financial statements. The filing does not contain specific financial fi
• Xilio Therapeutics Raises $15M in Private Placement — Dec 19, 2024 Risk: medium
  On December 18, 2024, Xilio Therapeutics, Inc. announced the closing of its previously disclosed private placement of common stock. The company raised approxima
• Xilio Therapeutics Faces Nasdaq Delisting Warning — Sep 13, 2024 Risk: high
  Xilio Therapeutics, Inc. announced on September 10, 2024, that it received a notification from The Nasdaq Stock Market LLC regarding its failure to meet the min
• Xilio Therapeutics Files 8-K on Shareholder Matters — Jun 17, 2024 Risk: low
  Xilio Therapeutics, Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders as of June 13, 2024. The filing details the
• Xilio Therapeutics Announces Board and Executive Changes — Jun 13, 2024 Risk: medium
  On June 13, 2024, Xilio Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the company
• Xilio Therapeutics Files 8-K: Material Agreement, Financials, and More — Mar 28, 2024 Risk: medium
  On March 27, 2024, Xilio Therapeutics, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The compa
• Xilio Therapeutics to be Delisted from Nasdaq Global Select Market — Jan 19, 2024
  Xilio Therapeutics, Inc. (XLO) announced on January 19, 2024, that it received a notice from Nasdaq indicating its common stock will be delisted from the Nasdaq
• Xilio Therapeutics Reports Officer/Director Changes, Comp Arrangements — Jan 3, 2024
  Xilio Therapeutics, Inc. filed an 8-K on January 3, 2024, reporting an event that occurred on January 1, 2024, related to the departure or election of directors

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX